2011 CMCE HallinanFrank
2011 CMCE HallinanFrank
2011 CMCE HallinanFrank
Frank Hallinan
EBE Biopharmaceutical Manufacturing
& CMC Conference
Barcelona, March 21, 2011
Agenda:
The Past
The Business Case & Future.
The Challenges:
Technical;
Regulatory.
Approaches to Meet those Challenges:
Quality Risk Management;
Single Use Approaches;
EBE Multi Purpose Use Concept Paper.
Conclusions.
Questions.
1
The Past:
Increasing Titers;
More Products but less Blockbusters;
Personalised Medicine.
Cost Issues:
Technology Issues:
Tomorrows Facility:
Long-standing facility design paradigms are changing -
Operational Complexity:
Multi Product;
Multi Phase;
Multi Platform.
Engineering Complexity:
Hardware Issues;
Software & Automation Issues.
Pharmacological Reactivity;
Immunological Reactivity.
EFPIA. TG
dedicated facilities, 2006
Disposables:
Internal Project within Pfizers Bio-process Plant of the
Future initiative:
Key themes
cost.
1990
Up To
750L
Storage
1995
Solid/LiquidSeparation
2005
Steamable
Connections
Sterile
Connectors
Sartorious
Pall
(Centrifugation,NormalFlow
orTFF)
Millipore
Hyclone
Chromatography
Roller Bottles
Unifuge
Lev
Tech
HyNetics
Mixing
CellCulture
2010
Up To
10,000L
Stedim
Tubing
Welders
Connections
2000
WAVE
Xcellerex
Hyclone
GE
Healthcare
References
Purpose
Scope
Regulatory Aspects
Methodology:
Segregation of Products
Risk Assessment:
Material
Environment
Equipment
Methods
People
Cleaning
Change-Over
15
16
17
1. Segregation of Products:
..appropriate controls to prevent cross
contamination
Segregation is due to a combination of Soft (ie
Procedural Controls) and Hard (ie Physical
controls) Boundaries which together minimise
risk of cross contamination.
2. Risk Assessment
3. Cleaning
4. Change-Over
19
1. Segregation of Products:
2. Risk Assessment:
Risk Assess Overall Operating Model:
Campaign/Parallel Processing
Select appropriate Operating Model
Risk Assess Each of the Operating Steps
Consider Categories of
Materials/Environment/Equipment/Methods/People
3. Cleaning
4. Change-Over
20
Closed Systems:
Single Use/Disposable equipment:
qualification/maintenance/calibration
Automation
Equipment Identification Practices
21
3. Cleaning:
Risk Assess Cleaning Processes/Validation
Cleaning Validation Strategy for New product based on
data with this product.
Intervals for monitoring of cleaning and revalidations
reassessed
4. Change-Over:
Clearly document processes and Procedures.
22
Conclusions:
broad understanding;
QRM is a proven tool in documenting that all concerns
have been adequately controlled;
EBE Concept Paper provides an effective framework for
using QRM as a Central Tool for achieving biotech
manufacturing facility flexibility.
Level of achieved flexibility is a function of:
The rigor of your risk management;
The effectiveness of your prospective engagement with BoH;
Questions: